Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes
- PMID: 9226005
- DOI: 10.1002/jlb.62.1.138
Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes
Abstract
Several anti-HIV drugs acting on different steps of virus replication were tested in our experimental model of primary monocyte/macrophages; the results were compared with the activity found in lymphocytes. Nucleoside analogues (AZT, ddI, ddC, d4T, PMEA, 3TC etc.) show greater activity in macrophages (M/M) than in lymphocytes. In particular, the EC50 of AZT, ddC, and ddI in M/M is 2- to 100-fold lower than that found in lymphocytes. This greater efficacy of nucleoside analogues in M/M depends on the enhancement of their chain-terminating activity by the low levels of endogenous deoxynucleoside-triphosphates (dNTP) usually found in resting cells such as M/M. Non-nucleoside reverse transcriptase inhibitors (NNRTI) do not act as chain terminators (thus their antiviral effect is not related to the intracellular concentrations of dNTP); as a consequence the activity of TSAO, HEPT, TIBO, and other NNRTI tested in M/M is similar to that found in lymphocytes. Regarding inhibitors of binding and fusion of HIV, we found that their anti-HIV activity is markedly decreased (or even nullified) when M/M are treated with cytokine activators of M/M function and enhancers of HIV replication. More relevant from a clinical standpoint, protease inhibitors are able to inhibit HIV replication in chronically infected macrophages (i.e., cells carrying the proviral genome already integrated in the host genome). All other inhibitors of late stage of virus life cycle tested (antisense-rev, anti-tat, interferon-alpha and -gamma, phosphorothioate analogues, GLQ-223, etc.) were totally inactive in chronically infected macrophages. The different effects of various classes of HIV inhibitors in lymphocytes and macrophages suggests that AIDS therapy should consider all aspects of the pathogenesis of HIV infection and must be restricted to drugs, or combinations of drugs, active against both lymphocytes and M/M in all body compartments where the virus hides and replicates.
Similar articles
-
Antiviral profile of HIV inhibitors in macrophages: implications for therapy.Curr Top Med Chem. 2004;4(9):1009-15. doi: 10.2174/1568026043388565. Curr Top Med Chem. 2004. PMID: 15134554 Review.
-
Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir.Antiviral Res. 2002 Aug;55(2):209-25. doi: 10.1016/s0166-3542(02)00052-9. Antiviral Res. 2002. PMID: 12103427 Review.
-
Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.Antivir Chem Chemother. 2000 Nov;11(6):353-8. doi: 10.1177/095632020001100601. Antivir Chem Chemother. 2000. PMID: 11227992
-
In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages.J Leukoc Biol. 1994 Sep;56(3):381-6. doi: 10.1002/jlb.56.3.381. J Leukoc Biol. 1994. PMID: 8083612
-
Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.J Virol. 2007 May;81(9):4540-50. doi: 10.1128/JVI.01620-06. Epub 2007 Feb 7. J Virol. 2007. PMID: 17287264 Free PMC article.
Cited by
-
Longitudinal analysis of monocyte/macrophage infection in simian immunodeficiency virus-infected, CD8+ T-cell-depleted macaques that develop lentiviral encephalitis.Am J Pathol. 2006 May;168(5):1553-69. doi: 10.2353/ajpath.2006.050240. Am J Pathol. 2006. PMID: 16651622 Free PMC article.
-
The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.J Virol. 2001 May;75(9):4402-6. doi: 10.1128/JVI.75.9.4402-4406.2001. J Virol. 2001. PMID: 11287590 Free PMC article.
-
Evidence for a different susceptibility of primate lentiviruses to type I interferons.J Virol. 2013 Mar;87(5):2587-96. doi: 10.1128/JVI.02553-12. Epub 2012 Dec 19. J Virol. 2013. PMID: 23255800 Free PMC article.
-
Didanosine: an updated review of its use in HIV infection.Drugs. 1999 Dec;58(6):1099-135. doi: 10.2165/00003495-199958060-00009. Drugs. 1999. PMID: 10651392 Review.
-
HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection.PLoS Comput Biol. 2012 Jan;8(1):e1002359. doi: 10.1371/journal.pcbi.1002359. Epub 2012 Jan 19. PLoS Comput Biol. 2012. PMID: 22275860 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical